Cardiac remodeling-concepts and clinical implications: A consensus paper from an International Forum on Cardiac Remodeling

Journal of the American College of Cardiology

Volumn 35, Issue 3, 2000, Pages 569-582

  Cohn, Jay N ^a   Ferrari, Roberto ^b   Sharpe, Norman ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL; MILRINONE; PIMOBENDAN; PIPERANOMETOZINE; PLACEBO; PRAZOSIN; PROPRANOLOL; RAMIPRIL; TIMOLOL; TRANDOLAPRIL;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE OVERLOAD; HEART SCINTISCANNING; HEART SIZE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOPTOSIS; CARDIOTONIC AGENTS; CELL DIVISION; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; RADIONUCLIDE VENTRICULOGRAPHY; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 0034162004     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00630-0     Document Type: Article

References (132)

1. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
2. The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
3. Massie B.M., Fisher S.G., Deedwania P.C., Singh B.N., Fletcher R.D., Singh S.N. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 93:1996;2128-2134.
4. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
5. The effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
6. Waagstein F., Bristow M.R., Swedberg K., Camenini F., Fowler M.B., Silver M.A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
7. Packer M., Bristow M.R., Cohn J.N. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
8. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 349:1997;375-380.
9. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on morbidity and mortality in patients with heart failure Collaborative Group on ACE-Inhibitor Trials . JAMA. 273:1995;1450-1456.
10. Effect of metoprolol CR/XL in chronic heart failure metoprolol CR/XL randomized intervention trial in congestive heart failure . Lancet. 353:1999;2001-2007.
11. Randomized Aldactone Evaluation Study (RALES) report presented at the American Heart Association meeting. November 14-16, 1998.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II) a randomized trial . Lancet. 353:1999;9-13.
13. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 29:1997;1060-1066.
14. Konstam M.A., Rousseau M.F., Kronenberg M.W., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 86:1992;431-438.
15. Konstam M.A., Kronenberg M.W., Rousseau M.F., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 88:1993;2277-2283.
16. Greenberg B., Quinones M., Kolpillai C., et al. Effect of long-term enalapril on cardiac structure and function in patients with left ventricular dysfunction. Circulation. 91:1995;2573-2581.
17. Eaton L.W., Bulkley B.H. Expansion of acute myocardial infraction its relationship to infarct morphology in a canine model . Circ Res. 49:1981;80-88.
18. Hochman J.S., Bulkley B.H. Expansion of acute myocardial infarction; an experimental study. Circulation. 65:1982;1446-1450.
19. Korup E., Dalsgaard D., Nyvad O., Jensen T.M., Toft E., Berning J. Comparisons of degrees of left ventricular dilation within 3 hours and up to 6 days after onset of first acute myocardial infarction. Am J Cardiol. 80:1997;449.
20. Hutchins G.M., Bulkley B.H. Infarct expansion extension two different complications of acute myocardial infarction . Am J Cardiol. 41:1978;1127-1133.
21. Weisman H., Bush D.E., Mannisi J.A., Bulkley B.H. Global cardiac remodeling after acute myocardial infarction a study in the rat model . Am J Cardiol. 5:1985;1355-1362.
22. Rumberger J.A., Behrenbeck T., Breen J.R., Reed J.E., Gersh B.J. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol. 21:1993;673-682.
23. Jugdutt B.I. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol. 25:1995;1718-1725.
24. Anversa P., Olivetti G., Capasso J.M. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol. 68:1991;7D-16D.
25. McKay R.G., Pfeffer M.A., Pasternak R.C., Markis J.E., Come P.C., Nakao S. Left ventricular remodeling after myocardial infarction a corollary to infarct expansion . Circulation. 74:1986;693-702.
26. Gaudron P., Eilles C., Kugler I., Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Circulation. 87:1993;755-763.
27. Olivetti G., Capasso J.M., Sonnenblick E.H., Anversa P. Side-to-side slippage of myocytes in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res. 67:1990;23-34.
28. Weber K.T., Brilla C.G. Pathological hypertrophy and the cardiac interstitium fibrosis and the renin-angiotensin-aldosterone system . Circulation. 83:1991;1849-1865.
29. White H.D., Norris R.M., Brown M.A., Brandt P.W.T., Whitlock R.M.L., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from endomyocardial infarction. Circulation. 76:1987;44-51.
30. Douglas P.S., Morrow R., Ioli A., Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 13:1989;311-315.
31. Mitchell G.F., Lamas G.A., Vaughan D.E., Pfeffer M.A. Left ventricular remodeling in the year after first anterior myocardial infarction a quantitative analysis of contractile segment lengths and ventricular shape . J Am Coll Cardiol. 19:1992;1136-1144.
32. Grossman W., Jones D., McLaurin L.D. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 56:1975;56-64.
33. Hirose K., Shu N.H., Reed J.E., Rumberger J.A. Right ventricular dilatation and remodeling the first year after an initial transmural wall left ventricular myocardial infarction. Am J Cardiol. 72:1993;1126-1130.
34. Struijker-Boudier H.A.J., Smits J.F.M., DeMey J.G.R. Pharmacology of cardiac and vascular remodeling. Ann Rev Pharmacol Toxicol. 35:1995;509-539.
35. Tan L.B., Jalil J.E., Pick R., Janicki J.S., Weber K.T. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 69:1991;1185-1195.
36. Sharov V.G., Sabbah H.N., Shimoyama H., Goussev A.V., Lesch M., Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 148:1996;141-149.
37. Teiger E., Dam T.-V., Richard L., et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 97:1996;2891-2897.
38. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A. Apoptosis in the failing human heart. N Engl J Med. 336:1997;1131-1141.
39. Anderson K.R., Sutton M.G., Lie J.T. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 128:1978;79-85.
40. Weber K.T., Pick R., Silver M.A., Moe G.W., Janicki J.S., Zucker I.H. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 82:1990;1387-1401.
41. Villareal F.J., Kim N.N., Ungab G.D., Printz M.P., Dillmann W.H. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 88:1993;2849-2861.
42. Reiss K., Capasso J.M., Huang H.E., Meggs L.G., Li P., Anversa P. ANG II receptors, c-myc and c-jun in myocytes after myocardial infarction and ventricular failure. Am J Physiol. 264:1993;H760-H769.
43. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 73:1993;413-423.
44. Everett A.D., Tufro-McReddie A., Fisher A., Gomez R.A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension. 23:1994;587-592.
45. Belch J.J.F., Bridges A.B., Scott N., Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 65:1991;245-248.
46. Ferrari R., Agnoletti L., Comini L., et al. Oxidative stress during myocardial ischemia and heart failure. Eur Heart J. 19:(Suppl B):1998;S138-S141.
47. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
48. Rumberger J.A. Ventricular dilation and remodeling after myocardial infarction. Mayo Clinic Proc. 69:1994;664-674.
49. Chidsey C., Braunwald E., Morrow A.G., Mason D.T. Myocardial norepinephrine concentrations in man. N Engl J Med. 269:1963;653-658.
50. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 82:1990;1724-1729.
51. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe heart failure. N Engl J Med. 323:1990;236-241.
52. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies of Left Ventricular Dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
53. McClure S., Carunana L., Davie A.P., et al. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ. 317:1998;516-519.
54. Vantrimpont P., Rouleau J.L., Ciampi A., et al. Two-year course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur Heart J. 19:1998;1552-1563.
55. Sadoshima J., Xu Y., Slayter H.S., et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vivo. Cell. 75:1993;977-984.
56. Ollivier J-P, Bouchet VA. Prospects for cardioreparation. Am J Cardiol 1992;70:27-36C.
57. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts response to angiotensin II and aldosterone . J Mol Cell Immunol. 26:1994;809-820.
58. Sheehan J.P., Seelig M.S. Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium. 3:1984;301-314.
59. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
60. Kiowski W., Sutsch G., Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
61. A blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental models of heart failure. Circ Res. 39:1998;600-608.
62. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in cachectic patients with severe chronic heart failure. Br Heart J. 66:1991;356-358.
63. Bozkurt B., Kribbs S.B., Clubb F.J. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
64. Ferrari R., Ceconi C., Curello S., Cargoni A., Pasini E., Visiolo O. The occurrence of oxidative stress during reperfusion in experimental animals and men. Cardiovasc Drug Ther. 5:1991;277-288.
65. McMurray J., Chopra M., Abdullah I., Smith W.E., Dargie H.F. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 14:1993;1493-1498.
66. Singh N., Dhalla K., Seneviratne C., Singal P.K. Oxidative stress and heart failure. Mol Cell Biochem. 147:1995;77-81.
67. Hill M.F., Singal P.K. Antioxidant and oxidative stress changes during heart failure subsequent myocardial infarction in rats. Am J Pathol. 148:1996;291-300.
68. Polunovsky V.A., Wendt C.H., Ingbar D.H., Peterson M.S., Bittermann P.B. Induction of endothelial cell apoptosis by TNF alpha modulation by inhibitors of protein synthesis. Exp Cell Res. 214:1994;584-594.
69. 2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase. Arterioscler Throm Vasc Biol. 17:1997;3588-3592.
70. Francis G.S., McDonald K.M. Left ventricular hypertrophy an initial response to myocardial injury . Am J Cardiol. 69:1992;3G-6G.
71. Dhalla NS, Kaura D, Liu X, Beamish RE. Mechanisms of subcellular remodeling in postinfarct heart failure. In: Konstam M, editor. Myocardial Ischemia: Mechanisms, Reperfusion, Protection. Birkhauser Verlag Basel: Basel, Switzerland 1996:463-77.
72. Van Krimpen C., Smits J.F.M., Cleutjens J.P.N., et al. DNA synthesis in the noninfarcted cardiac interstitium after left coronary artery ligation in the rat effect of captopril . J Mol Cell Cardiol. 23:1991;1245-1253.
73. Volders P.G.A., Willems I.E.M.G., Cleutjens J.P.M., et al. Interstitial collagen is increased in the noninfarcted human myocardium after myocardial infarction. J Mol Cell Cardiol. 25:1993;1317-1323.
74. Tyagi S.C., Matsubara L., Weber K.T. Direct extraction and estimation of collagenase(s) activity by zymograph in microquantities of rat myocardium and uterus. Clin Biochem. 26:1993;191-198.
75. Cleutjens J.P.M., Kandala J.C., Guarda E., Guntaka R.V., Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 27:1995;1281-1292.
76. Delong M.J. Apoptosis a modulator of cellular homeostasis and disease states . Ann NY Acad Sci. 842:1998;82-90.
77. Kajstura J., Leri A., Finato N., di Loreto C., Bertrami C.A., Anversa P. Myocyte proliferation in end stage cardiac failure in humans. Proc Natl Acad Sci. 95:1998;8801-8805.
78. Meerson FZ. The failing heart: adaptation and deadaptation: XVII. In: Katz J, Editor. Translated from Russian by Nicholas Bobrov and Leonid Levant. New York: Raven Press, 1983.
79. Sabbah H.N., Goldstein S. Ventricular remodeling consequences and therapy . Eur Heart J. 14:(Suppl C):1993;24-29.
80. Hammermeister K.E., DeRouen T.A., Dodge H.T. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic and quantitative angiographic values. Circulation. 59:1979;421-430.
81. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Circulation. 81:1990;1161-1172.
82. Carr A., Prisant M., Watkins L. Detection of hypertensive left ventricular hypertrophy. Hypertension. 7:1985;948-954.
83. Kannel W.B. Need and prospects for prevention of heart failure. Eur J Clin Pharmacol. 49:1996;S3-S9.
84. Cohn J.N., Johnson G.R., Shabetai R., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:(Suppl VI):1993;VI5-VI16.
85. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
86. Lechat P., Escolano S., Golmard J.L. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 96:1997;2197-2205.
87. White H.D., Norris R.M., Brown M.A., Brandt P.W.T., Whitlock R.M.L., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51.
88. Cleland J.G.F. Guidelines for the diagnosis of heart failure. Eur Heart J. 16:1995;741-751.
89. McDonagh T.A., Morrison C.E., Lawrence A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 350:1997;829-833.
90. McMurray J.J.V., Davie A.P., McDonagh T.A. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J. 19:1998;842-846.
91. Gottdiener J.S. Left ventricular mass, diastolic dysfunction and hypertension. Ann Intern Med. 38:1993;31-56.
92. Francis C.M., Caruna L., Kearney P., et al. Open access echocardiography in management of heart failure in the community. Br Med J. 310:1995;634-636.
93. Krzesinski J.M., Rorive G., Cauwenberge V. Hypertension and left ventricular hypertrophy. Acta Cardiologica. 51:1996;143-154.
94. Gradman A., Deedwania P., Cody R., et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol. 14:1989;464-470.
95. Parameshwar J., Keegan J., Sparrow J., Sutton G.C., Poole-Wilson P.A. Predictors of prognosis in severe chronic heart failure. Am Heart J. 123:1992;421-426.
96. Likoff M.J., Chandler S.L., Kay H.F. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 59:1987;634-638.
97. Cintron G., Johnson G., Francis G., Cobb F., Cohn J.N. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 87:(Suppl V):1993;VI17-VI23.
98. Cowie M.R., Struthers A.D., Wood D.A. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
99. Ferrari R., Ceconi C. Neuroendocrine activation in left ventricular dysfunction [editorial]. Eur Heart J. 19:1998;1423-1424.
100. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
101. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 83:1991;52-60.
102. Cohn J.N., Ziesche S., Smith R., et al. Effect of the calcium antagonist felodipine as supplementary therapy in patients with chronic heart failure treated with enalapril VHeFT III . Circulation. 96:1997;856-863.
103. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1:1988;253-259.
104. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction results of the Cooperative New Scandinavian Survival Study II (CONSENSUS II) . N Engl J Med. 327:1992;678-684.
105. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
106. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
107. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
108. GISSI 3 Effects of lisinopril and transdermal glyceryl trinitrate singly and together on six-week mortality and ventricular function after acute myocardial infarction . Lancet. 343:1994;1115-1122.
109. Nicolosi G.L., Latini R., Marino P., et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects if early lisinopril treatment on left ventricular structure and function after myocardial infarction in the GISSI-3 trial. Eur Heart J. 17:1996;1646-1656.
110. A randomized trial of beta-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
111. Colucci W.S., Packer M., Bristow M.R., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
112. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
113. Gilbert E.M., Anderson J.L., Deitchman D., et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind randomized study of bucindolol versus placebo . Am J Med. 88:1990;223-229.
114. Lowes B.D., Gill E.A., Abraham W.T., et al. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol. 83:1999;1201-1205.
115. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled randomized trial. Circulation. 96:1997;183-191.
116. A Randomized trial of propranolol in patients with acute myocardial infarction. J Am Med Assoc. 247:1982;1707-1714.
117. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
118. Cohn J.N. Vasodilator therapy for heart failure the influence of impedance on left ventricular performance . Circulation. 48:1973;5-8.
119. McDonald K.M., Francis G.S., Matthews J.H., Hunter D., Cohn J.N. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol. 21:1993;514-522.
120. Lubsen J., Just H., Hjalmarsson A.C., et al. Effect of pimobendan on exercise capacity in patients with heart failure main results from the Pimobendan in Congestive Heart Failure (PICO) trial . Heart. 76:1996;223-231.
121. Hampton J.R., van Veldhuisen D.J., Kleber F.X., et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 349:1997;971-977.
122. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 339:1998;1810-1816.
123. Beckwith C., Munger M.A. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother. 27:1993;755-766.
124. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med. 317:1987;787-792.
125. Woodley S.L., Gilbert E.M., Anderson J.L., et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
126. Packer M., Colucci W.S., Sackner-Bernstein J.D., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation. 94:1996;2793-2799.
127. Cohn J.N., Fowler M.B., Bristow M.R., et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 3:1997;173-179.
128. Waagstein F., Caidahl K., Wallentin I., Bergh C.H., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 80:1989;551-563.
129. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., Eichorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.
130. Kukin M.L., Kalman J., Charney R.H., et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation. 99:1999;2645-2651.
131. Packer M. Beta-adrenergic blockade in chronic heart failure principles, progress and practice . Prog Cardiovasc Dis. 41:(Suppl 1):1998;39-52.
132. Sackner-Bernstein J.D. Use of carvedilol in chronic heart failure challenges of therapeutic management . Prog Cardiovasc Dis. 41:(Suppl 1):1998;53-58.